Head-to-head · Value Score
CoreAge Rx vs Willow
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, Willow a 62. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$99/mo
Save ~89% vs brand-nameWillow
#367 · Grade C · Watch List
Est. first month
From $299/mo (starting dose, compounded)
Save ~78% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 62 — an est. $99/mo first month, with no teaser step-up baked in. Willow isn't out of it: Someone who wants a needle-free tablet option from a program that prices it openly.
CoreAge Rx is also our overall #1 pick across the whole deals ranking — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | Willow |
|---|---|---|
| Value Score | 93 (A+) | 62 (C) |
| Est. first month | $99/mo | From $299/mo (starting dose, compounded) |
| Save vs brand-name | ~89% | ~78% |
| Semaglutide | $99/mo | From $299/mo (starting dose, compounded) |
| Tirzepatide | $149/mo | From $399/mo (starting dose, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Willow
Willow sells compounded semaglutide and tirzepatide in both weekly injections and under-the-tongue tablets, publishing $299 a month for semaglutide on its own product page.
Why it's a deal
- Publishes the semaglutide rate on the product page at $299 a month rather than holding it until after an intake
- Offers both molecules in tablet form as well as injection, so the needle is optional on either route
- Runs its own semaglutide-versus-tirzepatide comparison rather than steering every visitor to one product
- Shipments can be adjusted rather than fixed to a rigid schedule
The fine print
- $299 for semaglutide sits well above the roughly $179 median across the programs tracked here, and the tirzepatide rate is higher again
- The states it serves are not published anywhere on the site
- Compounded only — no FDA-approved brand-name option
- The pharmacy that compounds the medication is not named, and no 503A or 503B designation is given
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives ranking, and the same list for the other side is on alternatives to Willow.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.